多发性骨髓瘤的治疗进展

白血病·淋巴瘤 Pub Date : 2020-03-25 DOI:10.3760/CMA.J.CN115356-20200201-00028

Zeyu Lin

{"title":"多发性骨髓瘤的治疗进展","authors":"Zeyu Lin","doi":"10.3760/CMA.J.CN115356-20200201-00028","DOIUrl":null,"url":null,"abstract":"The clinical study of multiple myeloma at various stages has been reported at 2019 American Society of Hematology Annual Meeting. This article focuses on several key studies of the treatment of high-risk smoking multiple myeloma (HR-SMM), newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM), especially the chimeric antigen receptor T-cell (CAR-T) therapy, in order to guide clinical selection of better treatment options. However, most of these studies are phase Ⅰ-Ⅱ studies, and the median follow-up period is short, the long-term follow-up and the results of phase Ⅲ studies with enlarged samples are needed to further determine the effectiveness and safety of each treatment plan. \n \n \nKey words: \nMultiple myeloma; Treatment; Immunotherapy","PeriodicalId":16246,"journal":{"name":"白血病·淋巴瘤","volume":"29 1","pages":"132-135"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment progress of multiple myeloma\",\"authors\":\"Zeyu Lin\",\"doi\":\"10.3760/CMA.J.CN115356-20200201-00028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The clinical study of multiple myeloma at various stages has been reported at 2019 American Society of Hematology Annual Meeting. This article focuses on several key studies of the treatment of high-risk smoking multiple myeloma (HR-SMM), newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM), especially the chimeric antigen receptor T-cell (CAR-T) therapy, in order to guide clinical selection of better treatment options. However, most of these studies are phase Ⅰ-Ⅱ studies, and the median follow-up period is short, the long-term follow-up and the results of phase Ⅲ studies with enlarged samples are needed to further determine the effectiveness and safety of each treatment plan. \\n \\n \\nKey words: \\nMultiple myeloma; Treatment; Immunotherapy\",\"PeriodicalId\":16246,\"journal\":{\"name\":\"白血病·淋巴瘤\",\"volume\":\"29 1\",\"pages\":\"132-135\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"白血病·淋巴瘤\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.CN115356-20200201-00028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"白血病·淋巴瘤","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115356-20200201-00028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

2019年美国血液学学会年会报道了多发性骨髓瘤不同阶段的临床研究。本文重点研究了高危吸烟型多发性骨髓瘤（HR-SMM）、新诊断型多发骨髓瘤（NDMM）和复发/难治性多发性肿瘤（RRMM）的治疗，特别是嵌合抗原受体T细胞（CAR-T）治疗，以指导临床选择更好的治疗方案。然而，这些研究大多是Ⅰ-Ⅱ期研究，中位随访期短，需要长期随访和扩大样本的Ⅲ期研究结果，以进一步确定每个治疗方案的有效性和安全性。关键词：多发性骨髓瘤；治疗；免疫疗法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Treatment progress of multiple myeloma

The clinical study of multiple myeloma at various stages has been reported at 2019 American Society of Hematology Annual Meeting. This article focuses on several key studies of the treatment of high-risk smoking multiple myeloma (HR-SMM), newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM), especially the chimeric antigen receptor T-cell (CAR-T) therapy, in order to guide clinical selection of better treatment options. However, most of these studies are phase Ⅰ-Ⅱ studies, and the median follow-up period is short, the long-term follow-up and the results of phase Ⅲ studies with enlarged samples are needed to further determine the effectiveness and safety of each treatment plan. Key words: Multiple myeloma; Treatment; Immunotherapy

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

白血病·淋巴瘤 Medicine-Oncology

自引率

0.00%

发文量

6278

期刊介绍： The JLL is a specialized academic journal that carries articles on hematological malignancies, and mainly about leukemia and lymphoma, involving the fields of medicine, chemistry, biology, etc. The purposes are to reflect the scientific results and the academic trends in the hematological malignancy field. It paid attention on both the basic research and clinical work, but more on the clinical side; on combining popularization with the raising of standards, but more on the raising of standards, in order to provide a field for exchanging experience, inspiring mutually and linking up information for those working for the basic research and clinical diagnosis and treatment in the field of leukemia and lymphoma. It is intended for high and middle ranking medical staffs.